Apyx Medical (APYX) Q2 FY26 earnings call

Apyx Medical delivered robust second-quarter results, primarily fueled by the strong performance of its Surgical Aesthetics segment and the growing adoption of the AYON platform. The company expanded AYON's capabilities with FDA clearance for power liposuction, which is expected to further enhance its market position. Management reaffirmed full-year revenue and margin guidance, expressing confidence in continued growth and liquidity into 2028, despite ongoing OEM segment decline and increased cash usage in operations.